Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael A. Schwarzschild, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
1985
Markey Fellowship award, HMS
1987 - 1988
Ryan Fellowship award, HMS
1994 - 1999
Clinical Investigator Development Award, NIH
1999 - 2002
George C. Cotzias Memorial Fellowship Award, APDA
2001
Fox Foundation inaugural research grant program award Awardee
2002 - 2005
Paul Beeson Faculty Scholar in Aging Research Program awardee, AFAR
2005 - 2006
Dorothy Dillon Eweson Lectureships, AFAR
2006
Partners in Excellence Award (mentoring)
2012 - 2018
Elected Chair, Executive Committee, Parkinson Study Group
2013
Member, Linked Clinical Trials Committee, Cure Parkinson's Trust
2018 - 2024
Elected Chair, Executive Committee, Parkinson Study Group
2017 - 2019
Scientific Advisory Board member, Michael J. Fox Foundation for Parkinson's Research

Overview

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01NS110879 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2019 - May 31, 2024
    NIH
    Urate-LRRK2 interactions in Parkinson's disease
    Role: Principal Investigator
  2. R13NS111953 (SCHWARZSCHILD, MICHAEL A) Apr 1, 2019 - Mar 31, 2022
    NIH
    2019 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  3. U01NS107009 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2018 - Apr 30, 2023
    NIH
    Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts
    Role: Principal Investigator
  4. U13NS103523 (SCHWARZSCHILD, MICHAEL A) Jul 1, 2017 - Jun 30, 2018
    NIH
    2017 Parkinson Study Group Symposium and Training
    Role: Principal Investigator
  5. R13NS098746 (SCHWARZSCHILD, MICHAEL A) Aug 1, 2016 - Jul 31, 2017
    NIH
    2016 Parkinson Study Group Symposium and Training
    Role: Principal Investigator

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Walk D, Nicholson K, Locatelli E, Chan J, Macklin EA, Ferment V, Manousakis G, Chase M, Connolly M, Dagostino D, Hall M, Ostrow J, Pothier L, Lieberman C, Gelevski D, Randall R, Sherman AV, Steinhart E, Grasso Walker D, Walker J, Yu H, Wills AM, Schwarzschild MA, Beukenhorst AL, Onnela JP, Berry JD, Cudkowicz ME, Paganoni S. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle Nerve. 2023 Feb 25. PMID: 36840949.
    Citations:    Fields:    
  2. Di Luca DG, Macklin EA, Hodgeman K, Lopez G, Pothier L, Callahan KF, Lowell J, Chan J, Videnovic A, Lungu C, Lang AE, Litvan I, Schwarzschild MA, Simuni T. Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials. Neurol Clin Pract. 2023 Feb; 13(1):e200113. PMID: 36865634; PMCID: PMC9973288.
    Citations:    
  3. Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Ravina B, Shoulson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR. Mitochondrial haplogroups and cognitive progression in Parkinson's disease. Brain. 2023 01 05; 146(1):42-49. PMID: 36343661.
    Citations: 1     Fields:    Translation:HumansCells
  4. Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855. PMID: 36203214; PMCID: PMC9535216.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  5. Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology. 2022 08 16; 99(7 Suppl 1):34-41. PMID: 35970592.
    Citations:    Fields:    Translation:Humans
  6. Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. Neurology. 2022 08 16; 99(7 Suppl 1):76-83. PMID: 35970586.
    Citations: 1     Fields:    Translation:Humans
  7. Crotty GF, Keavney JL, Alcalay RN, Marek K, Marshall GA, Rosas HD, Schwarzschild MA. Planning for Prevention of Parkinson Disease: Now Is the Time. Neurology. 2022 08 16; 99(7 Suppl 1):1-9. PMID: 36219787.
    Citations:    Fields:    Translation:Humans
  8. Molsberry SA, Hughes KC, Schwarzschild MA, Ascherio A. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts. Neurology. 2022 08 16; 99(7 Suppl 1):26-33. PMID: 35970591; PMCID: PMC9259088.
    Citations:    Fields:    Translation:Humans
  9. Zhang X, Molsberry SA, Schwarzschild MA, Ascherio A, Gao X. Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease. JAMA Netw Open. 2022 08 01; 5(8):e2227738. PMID: 35984656; PMCID: PMC9391952.
    Citations:    Fields:    Translation:Humans
  10. Luo S, Zou H, Stebbins GT, Schwarzschild MA, Macklin EA, Chan J, Oakes D, Simuni T, Goetz CG. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914. PMID: 35841312; PMCID: PMC9897939.
    Citations:    Fields:    
  11. Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Mol Neurodegener. 2022 02 23; 17(1):16. PMID: 35197079; PMCID: PMC8867846.
    Citations:    Fields:    Translation:HumansAnimalsCells
  12. Sanchez AV, Ison JM, Hemley H, Willis A, Siddiqi B, Macklin EA, Ulysse C, Reynolds M, Schwarzschild MA, Jackson JD. Designing the Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease study. Contemp Clin Trials. 2022 04; 115:106713. PMID: 35202842.
    Citations:    Fields:    Translation:Humans
  13. Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. 2022 03 08; 98(10):e1064-e1076. PMID: 35082171; PMCID: PMC8967390.
    Citations: 1     Fields:    Translation:Humans
  14. Page A, Yung N, Auinger P, Venuto C, Glidden A, Macklin E, Omberg L, Schwarzschild MA, Dorsey ER. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digit Biomark. 2022; 6(1):1-8. PMID: 35224425; PMCID: PMC8832247.
    Citations:    
  15. Macklin EA, Ascherio A, Schwarzschild MA. Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply. JAMA. 2022 01 04; 327(1):85-86. PMID: 34982121.
    Citations:    Fields:    Translation:Humans
  16. Darweesh SKL, De Vries NM, Helmich RC, Verbeek MM, Schwarzschild MA, Bloem BR. Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease. J Parkinsons Dis. 2022; 12(5):1419-1422. PMID: 35466957; PMCID: PMC9398068.
    Citations:    Fields:    Translation:Humans
  17. Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939. PMID: 34519802; PMCID: PMC8441591.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  18. Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, Schwarzschild MA, Sieber BA, Simuni T, Surmeier DJ, Tamiz A, Werner MH, Wright CB, Wyse R. Seeking progress in disease modification in Parkinson disease. Parkinsonism Relat Disord. 2021 09; 90:134-141. PMID: 34561166.
    Citations: 1     Fields:    Translation:Humans
  19. Bjornevik K, O'Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, Schwarzschild MA, Benkert P, Kuhle J, Ascherio A. Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology. 2021 Aug 11. PMID: 34380747; PMCID: PMC8575132.
    Citations:    Fields:    
  20. Flores-Torres MH, Hughes KC, Molsberry S, Gao X, Kang JH, Schwarzschild MA, Ascherio A. Cognitive function in men with non-motor features of Parkinson's disease. BMJ Neurol Open. 2021; 3(1):e000112. PMID: 34250483; PMCID: PMC8217956.
    Citations:    
  21. Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Herrington TM, Ravina B, Shoulson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, Amr SS, van Hilten JJ, Kasten M, Mollenhauer B, Trenkwalder C, Klein C, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet. 2021 06; 53(6):787-793. PMID: 33958783; PMCID: PMC8459648.
    Citations: 11     Fields:    Translation:HumansCells
  22. Mestre TA, Macklin EA, Ascherio A, Ferreira JJ, Lang AE, Schwarzschild MA. Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. Mov Disord. 2021 08; 36(8):1964-1967. PMID: 33942376.
    Citations: 1     Fields:    Translation:Humans
  23. Peters OM, Weiss A, Metterville J, Song L, Logan R, Smith GA, Schwarzschild MA, Mueller C, Brown RH, Freeman M. Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease. Neurobiol Dis. 2021 07; 155:105368. PMID: 33892050; PMCID: PMC8292971.
    Citations: 3     Fields:    Translation:AnimalsCells
  24. Zhang X, Molsberry SA, Pavlova M, Schwarzschild MA, Ascherio A, Gao X. Association of Sleepwalking and REM Sleep Behavior Disorder With Parkinson Disease in Men. JAMA Netw Open. 2021 04 01; 4(4):e215713. PMID: 33847749.
    Citations: 3     Fields:    Translation:Humans
  25. Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, Lyles KW. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. NPJ Parkinsons Dis. 2021 Mar 01; 7(1):16. PMID: 33649343.
    Citations: 1     
  26. Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021 03 01; 78(3):312-320. PMID: 33315105; PMCID: PMC7737147.
    Citations: 24     Fields:    Translation:Humans
  27. Hughes KC, Gao X, Baker JM, Stephen CD, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-Motor Features of Parkinson's Disease in Women. J Parkinsons Dis. 2021; 11(3):1237-1246. PMID: 33935102.
    Citations:    Fields:    Translation:Humans
  28. Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio A, Beck JC, Biglan K, Espay AJ, Tanner C, Oakes D, Shoulson I, Novak D, Kayson E, Ray Dorsey E, Mangravite L, Schwarzschild MA, Simuni T. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Ann Clin Transl Neurol. 2021 02; 8(2):308-320. PMID: 33350601.
    Citations: 4     Fields:    Translation:HumansCells
  29. Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism Relat Disord. 2020 11; 80 Suppl 1:S45-S53. PMID: 33349580.
    Citations: 4     Fields:    Translation:HumansAnimals
  30. Andronesi OC, Nicholson K, Jafari-Khouzani K, Bogner W, Wang J, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Schwarzschild MA, Cudkowicz M, Rosen BR, Paganoni S, Ratai EM. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Front Neurol. 2020; 11:590573. PMID: 33343494.
    Citations: 5     
  31. Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics. 2020 10; 17(4):1393-1405. PMID: 33205384; PMCID: PMC7851299.
    Citations: 5     Fields:    Translation:Humans
  32. Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord. 2020 10; 35(10):1727-1730. PMID: 33068466.
    Citations: 2     Fields:    Translation:Humans
  33. Ma C, Molsberry S, Li Y, Schwarzschild M, Ascherio A, Gao X. Dietary nicotine intake and risk of Parkinson disease: a prospective study. Am J Clin Nutr. 2020 10 01; 112(4):1080-1087. PMID: 32725131; PMCID: PMC7528555.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  34. Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020 12 15; 95(24):e3428-e3437. PMID: 32999056; PMCID: PMC7836665.
    Citations: 10     Fields:    Translation:Humans
  35. Bjornevik K, O'Reilly ÉJ, Cortese M, Furtado JD, Kolonel LN, Le Marchand L, Mccullough ML, Paganoni S, Schwarzschild MA, Shadyab AH, Manson JE, Ascherio A. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021 02; 22(1-2):133-143. PMID: 32985910; PMCID: PMC8004541.
    Citations: 4     Fields:    Translation:Humans
  36. Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson disease. Neurology. 2020 10 13; 95(15):e2095-e2108. PMID: 32817391; PMCID: PMC7713746.
    Citations: 6     Fields:    Translation:Humans
  37. Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Front Aging Neurosci. 2020; 12:186. PMID: 32636740.
    Citations: 4     
  38. Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR. ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696. PMID: 32540937; PMCID: PMC7455354.
    Citations: 11     Fields:    Translation:Humans
  39. Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 03 17; 94(11):481-494. PMID: 32102975; PMCID: PMC7220234.
    Citations: 28     Fields:    Translation:Humans
  40. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2020 Feb; 22(2):448. PMID: 31772350; PMCID: PMC7000320.
    Citations:    Fields:    
  41. Palacios N, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study. Parkinsons Dis. 2020; 2020:4038375. PMID: 32399169; PMCID: PMC7201469.
    Citations: 1     
  42. Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism Relat Disord. 2020 02; 71:58-59. PMID: 31948788.
    Citations:    Fields:    Translation:Humans
  43. Schootemeijer S, van der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, Schwarzschild MA, de Vries NM, Bloem BR. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease. J Parkinsons Dis. 2020; 10(4):1293-1299. PMID: 32925106.
    Citations: 17     Fields:    Translation:Humans
  44. Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? J Parkinsons Dis. 2020; 10(4):1571-1576. PMID: 32773396.
    Citations:    Fields:    Translation:Humans
  45. Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. J Parkinsons Dis. 2020; 10(3):1011-1021. PMID: 32250318.
    Citations: 1     Fields:    Translation:Humans
  46. Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510. PMID: 32250320.
    Citations: 10     Fields:    Translation:Humans
  47. Shen Y, Li J, Schwarzschild M, Pavlova M, He S, Ascherio A, Wu S, Cui L, Gao X. Plasma urate concentrations and possible REM sleep behavior disorder. Ann Clin Transl Neurol. 2019 12; 6(12):2368-2376. PMID: 31714690; PMCID: PMC6917330.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  48. Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. 2019 12 03; 93(23):e2157-e2169. PMID: 31719136.
    Citations: 7     Fields:    Translation:Humans
  49. Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med. 2020 03; 22(3):574-580. PMID: 31680121; PMCID: PMC7056638.
    Citations: 8     Fields:    Translation:Humans
  50. Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, Curhan GC, Ascherio A. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338. PMID: 31484712; PMCID: PMC6814412.
    Citations: 13     Fields:    Translation:Humans
  51. Bakshi R, Macklin EA, Schwarzschild MA. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Ann Neurol. 2019 08; 86(2):326-327. PMID: 31148194.
    Citations:    Fields:    Translation:Humans
  52. Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2089-e2100. PMID: 30926684.
    Citations: 15     Fields:    Translation:Humans
  53. Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019 04; 85(4):593-599. PMID: 30761591.
    Citations: 18     Fields:    Translation:Humans
  54. Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019 02 12; 92(7):329-337. PMID: 30745444; PMCID: PMC6382364.
    Citations: 56     Fields:    Translation:Humans
  55. Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Mov Disord. 2019 01; 34(1):7-8. PMID: 30653733.
    Citations: 1     Fields:    Translation:Humans
  56. Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A. Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2081-e2088. PMID: 30429276.
    Citations: 4     Fields:    Translation:Humans
  57. Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268. PMID: 30415890.
    Citations: 4     Fields:    Translation:HumansAnimals
  58. Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533. PMID: 30564619; PMCID: PMC6292193.
    Citations: 7     Fields:    
  59. Bhattacharyya S, Macklin EA, Schwarzschild MA. Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1582. PMID: 30338966.
    Citations:    Fields:    Translation:Humans
  60. Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Mov Disord. 2018 09; 33(9):1492-1496. PMID: 30218460.
    Citations: 14     Fields:    Translation:Humans
  61. Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. J Neurol Sci. 2018 11 15; 394:41-44. PMID: 30212740.
    Citations: 5     Fields:    Translation:Humans
  62. Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018 12; 89(12):1288-1295. PMID: 30076266.
    Citations: 8     Fields:    Translation:Humans
  63. Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol Cell Neurosci. 2018 10; 92:12-16. PMID: 29928993.
    Citations: 10     Fields:    Translation:AnimalsCells
  64. Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism Relat Disord. 2018 08; 53:4-9. PMID: 29789205.
    Citations: 2     Fields:    Translation:Humans
  65. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018 05 08; 90(19):e1646-e1653. PMID: 29643081.
    Citations: 8     Fields:    Translation:Humans
  66. Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018 Mar; 29:13-22. PMID: 29433982.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  67. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018 03; 33(3):414-420. PMID: 29318639; PMCID: PMC5839986.
    Citations: 6     Fields:    Translation:Humans
  68. O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):194-200. PMID: 29277115; PMCID: PMC6423442.
    Citations: 7     Fields:    Translation:Humans
  69. Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Mov Disord. 2017 11; 32(11):1501-1503. PMID: 28976040.
    Citations: 2     Fields:    Translation:Humans
  70. Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. Environ Health Perspect. 2017 08 18; 125(8):087011. PMID: 28886605; PMCID: PMC5783632.
    Citations: 10     Fields:    Translation:HumansPHPublic Health